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The adjusted hippocampal volume (aHV) on MRI, the standard uptake value ratio (SUVR) on FDG-PET and PIB-PET
SUVR measures were analyzed. The construction of the CCs domain scores, and the aHV on MRI and FDG-PET SUVR
measures, were replicated in the parental AB255 study database (n = 133 MCI). Partial correlations adjusted by age, gender,
and education were calculated with the associated p-value among every CC domain score and the neuroimaging biomarkers.
The results were replicated in the “MCI due to AD” with memory storage impairments from ADNI. Delayed Recall CC
domain score was significantly correlated with PIB-PET SUVR (= –0.61, p = 0.003) in the ACE study and also with aHV
on MRI (= 0.27, p = 0.01) and FDG-PET SUVR (= 0.27, p = 0.01) in the AB255 study. After a median survival time of
20.6 months, 85% from the ACE MCI converted to AD. The replication of our results in the ADNI dataset also confirmed our
findings. Delayed Recall is the CC domain score best correlated with neuroimaging biomarkers associated with prodromal
AD diagnosis.
Keywords: Alzheimer’s disease, amnestic mild cognitive impairment, amyloid, cognition, hippocampus, magnetic resonance
imaging, memory, positron emission tomography
INTRODUCTION
The search for reliable Alzheimer’s disease (AD)
biomarkers to identify prodromal AD [1, 2], or mild
cognitive impairment (MCI) due to AD [3], already
implemented or that has been proposed should be
used in clinical trials and clinical diagnosis [1, 3–7],
has focused on expensive methods which are often
poorly tolerated by patients (e.g., PET). By contrast,
neuropsychological tests are non-invasive, and may
be cost-effective, better predictors of disease than
neuroimaging [8]. The identification of optimal cog-
nitive composites (CCs) domains that are related to
neuroimaging biomarkers and that characterize spe-
cific phenotypes will maximize the cost-effectiveness
of clinical practice and management, and recruitment
into clinical trials.
In a recent study [9], atTheMemoryDisordersUnit
from Fundacio´ ACE (Barcelona, Spain) [10] which
involved the follow-up of 550 MCI subjects for an
average of 26.6 months, the present authors found
that the majority (45.5%) of those MCI individuals
who subsequently developed dementia displayed the
AD dementia phenotype.
The MCI subjects were classified as prob-
able/possible in function of the presence of
comorbidities that could otherwise explain their
cognitive deficits [9, 11–13]. Among those probable-
amnestic (Pr-a) MCI patients with memory storage
impairment [14] (i.e., impaired recall and recogni-
tion), there was an 8.5 times greater risk to develop
dementia, mainly AD, than those with the possi-
ble MCI condition, where cognitive deficits did not
include memory.
The aim of the present study was to find the opti-
mized CC domain scores that were most related
to three brain imaging biomarkers, derived from
structural magnetic resonance imaging (MRI), [18F]-
fluorodeoxyglucose-positron emission tomography
(FDG-PET), and Pittsburgh compound B-positron
emission tomography (PiB-PET) within the Pr-aMCI
storage phenotype.
MATERIALS AND METHODS
Subjects
For the purpose of this study, two groups of
datasets, >64 years old, were analyzed: (i) The
Fundacio´ ACE (ACE) study (n = 59) with 20 Pr-a-
MCI-storage subtype subjects (MCI, from now on)
(60.0% men) all with multiple domains impaired
and 39 healthy controls (HC) (51.3% men), were
all recruited and assessed from 2010 to 2013 at The
Memory Disorders Unit from Fundacio´ ACE, Insti-
tut Catala` de Neurocie`nces Aplicades, Barcelona,
Spain [10]. All subjects underwent a neuropsycho-
logical assessment including five cognitive domains
and were subjected to a structural MRI, FDG-PET,
and PIB-PET; and (ii) The parental AB255 study
(n = 175) with 133 MCI all with multiple domains
impaired and 42 HC, were all recruited and assessed
at 19 clinical memory research sites in Spain, Italy,
Sweden, and France and led by Araclon Biotech S.L.,
Zaragoza, Spain. The construction of the five CCs
domain scores, and the adjusted hippocampal volume
(aHV) on structural MRI, and the standard uptake
value ratio (SUVR) on FDG-PET measures, were
replicated in the parental AB255 study database.
The study was approved by the CEIC ethic commit-
tee 2009/5455, and all participants provided written
informed consent prior to inclusion.
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Clinical characteristics of the ACE study and the
AB255 study
All had the following inclusion criteria: aged
from 65 to 85; without lifetime history of psychi-
atric, neurological, or systemic illnesses; autonomy
for instrumental activities of daily living; preserved
global cognition (Mini-Mental State Examination,
MMSE) [15, 16] (≥ 24 scores); with general good
health; a Hachinski Ischemia Scale [17] score ≤ 4;
without depressive symptoms measured by self-
rating Geriatric Depression Scale [18] (< 11 scores);
at least minimal elementary school; without severe
auditory or visual abnormalities including glaucoma
and cataracts; and, DNA sample available. Those
subjects with significant vascular pathology on MRI
that could explain memory deficits, and/or with con-
traindications for neuroimaging administration, were
excluded from the study.
Diagnostic adjudication
The HC subjects had a normal clinical history for
their age, and no neurological signs or symptoms.
They did not report problems with memory or other
cognitive functions, and their performance on the
MMSE [15, 16], and measures of memory function
were normal. The Clinical Dementia Rating (CDR)
[19] was 0, and none had a family history of dementia.
The MCI patients fulfilled Petersen’s diagnostic
criteria [20], including subjective memory complaint,
relatively preserved performance in activities of daily
living, absence of dementia, and a measurable impair-
ment in memory function, with or without a deficit
in other cognitive domains [21]. They did not have
significant clinical comorbidities (i.e., cerebrovascu-
lar disease, history of head trauma encephalopathy,
infectious diseases, or developmental disabilities)
that could themselves cause cognitive deficits [12,
13]. The memory loss was characterized as being one
of impaired storage [14] because both verbal delayed
recall and recognition memory were impaired. The
CDR score was 0.5, with a 0.5 or 1 score for memory;
the Interview for Deterioration in Daily Activities in
Dementia score was less than 40 [22]. Those sub-
jects who converted to dementia, that is, to AD [5,
23], and mixed dementia (AD with cerebrovascu-
lar disease) over the study period, were classified as
MCI converters. All of them had a CDR [19] of 1.
In contrast, those subjects who remained stable dur-
ing follow-ups were classified as stable or non-MCI
converters.
Neuropsychological assessment
All subjects underwent a neuropsychological bat-
tery for diagnostic purposes, including evaluation
of i) global cognition using the MMSE [15, 16],
once adjusted by age and educational level; ii) ver-
bal learning and memory by The Word List Learning
test from the Wechsler Memory Scale-Third Edition
(WMS-III) [24], including delayed recall, and a
recognition task) without list of interference [25, 26],
and the Free and Cued Selective Reminding Test
(FCSRT) [27] adjusted by age and educational level;
and, iii) The Vocabulary test of the Wechsler Adult
Intelligence Scale-Third Edition (WAIS-III) [28], as
a previous cultural level estimation tool.
Comparison of demographic, genetic, and neu-
ropsychological data of these subjects are detailed
in Table 1. There were no statistically significant dif-
ferences between HC and MCI subjects in education
or gender, but they did differ in age (Cohen’s d = 1.00,
p = 0.001) (Table 1). The MCI patients had a higher
frequency of APOE 4 allele carriers (presence of
at least one 4 allele) compared to the HC subjects
(χ2 = 22.26, p < 0.001, Odds Ratio = 20.42). The MCI
patients had significantly lower scores in the Global
Cognition, Verbal Memory, and Vocabulary test com-
pared to the HC group (Table 1).
Cognitive composites construction
All subjects underwent a neuropsychological
battery with tests in five cognitive domains: 1)
Memory: Rey’s Auditory-Verbal Learning Test
(RAVLT) [29] and Alzheimer’s Disease Assessment
Scale-Cognitive Subscale (ADAS-Cog) [30] (only
immediate recall on memory condition); 2) Delayed
Recall: both verbal RAVLT [29] and ADAS-Cog [30]
also incorporating non-verbal (Rey-Osterrieth Com-
plex Figure Test, ROCF) [29]; 3) Processing Speed,
Attention, and Executive Functions: Digit Symbol
coding and Digit spans forwards and backwards [29],
Trail Making Test (part B-part A) [29]; Semantic
Verbal Fluency (“animals” during one minute) [29],
and Phonetic Verbal Fluency (words beginning with
“P” during one minute) [29]; 4) Language: Boston
Naming Test [29] and Commands item from the
ADAS-Cog [30]; and 5) Praxis: the ROCF copy con-
dition [29] and Block Design from WAIS-III [29].
In order to create the CCs domain scores, the data
were first analyzed by a principal component anal-
ysis (PCA). Five separate PCAs were performed,
one for each of the following cognitive domains: 1)
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Table 1
Demographic, genetic and neuropsychological data between HC and MCI subjects from the ACE study and the AB255 study
HC MCI Statistics p Effect size3
N (%) 39 (66.1) 20 (33.9)
42 (24.0) 133 (76.0)
Gender n (%) Male 20 (51.3) 12 (60.0) 0.591 0.360 0.70
21 (50.0) 64 (48.1) 0.041 0.832 1.08
Education in years 12.3 ± 4.1 10.6 ± 4.1 2.012 0.161 0.42
12.2± 3.9 15.4± 22.9 0.812 0.370 0.24
Age in years 71.3 ± 4.4 75.7 ± 4.4 13.152 0.001∗∗ 1.00
71.0± 4.5 74.0± 5.1 11.892 0.001∗∗ 0.63
APOE 4 n (%) 4 (10.3) 14 (70.0) 22.261 0.001∗∗ 20.42
(presence of 4 or 4/4) 4 (9.5) 73 (54.9) 26.661 0.001∗∗ 11.56
Neuropsychological battery
Global Cognition
MMSE 29.7 ± 0.6 26.0 ± 1.9 43.092 0.001∗∗ 2.96
29.7± 0.6 26.2± 2.2 104.092 0.001∗∗ 2.50
Verbal Memory
Verbal Learning and Memory WMS-III
Learning (Trials 1+2+3+4) 30.0 ± 5.2 16.0 ± 4.9 32.792 0.001∗∗ 2.77
29.6± 5.1 16.6± 4.8 227.902 0.001∗∗ 2.63
Delayed Recall 6.3 ± 2.8 0.3 ± 0.7 33.85 2 0.001∗∗ 3.43
6.1± 2.5 1.2± 1.7 210.04 2 0.001∗∗ 2.33
Recognition memory 22.3 ± 1.8 14.6 ± 2.7 53.842 0.001∗∗ 3.42
22.1± 1.8 15.3± 2.1 350.732 0.001∗∗ 3.49
Buschke Selective Reminding Test
Free recall (Trials 1+2+3) 23.7 ± 6.7 3.1 ± 3.0 58.802 0.001∗∗ 4.25
23.7± 6.7 6.1± 4.7 359.542 0.001∗∗ 3.09
Cued Recall (Trials 1+2+3) 18.9 ± 5.2 10.6 ± 6.2 12.112 0.001∗∗ 1.46
18.5± 5.0 11.9± 6.1 40.902 0.001∗∗ 1.19
Free + Cued Recall 42.5 ± 4.4 13.8 ± 7.9 107.152 0.001∗∗ 4.67
42.7± 4.4 17.9± 8.9 289.762 0.001∗∗ 3.73
Vocabulary test (WAIS-III) 13.9 ± 2.1 12.4 ± 2.4 4.112 0.011* 0.88
(Scalar Scores) 13.8± 2.1 11.8± 2.5 32.582 0.001∗∗ 1.05
Values in regular print correspond to ACE study and values in italic correspond to AB255 study; HC, healthy controls; MCI, amnestic mild
cognitive impairment-storage type; MMSE, Mini-Mental State Examination; WMS-III, Wechsler Memory Scale, Third Edition; Recognition
memory, correct answers WMS-III; WAIS-III, Wechsler Adult Intelligence Scale-Third Edition. Values reported are means:±; SD, standard
deviation; 1: χ2; 2: F; 3: Cohen’s d for continuous variables, and Odds ratio for categorical data are reported. *Statistically significant p≤ 0.01;
∗∗p≤ 0.001.
learning, 2) delayed recall on memory, 3) executive
functions, 4) language, and 5) praxis. Every PCA was
forced to produce a unidimensional factorial solution,
according to the expected unidimensional neuropsy-
chological function assessed. The original variables
contributed to the final score in a weighted way, based
on the magnitude of the inter-correlations among the
variables in the same composite domain. The stability
of the PCA was evaluated by means of the Hotelling’s
T2 test. When a neuropsychological variable obtained
a factorial loading <0.3 in the one-dimension solu-
tion, the variable was excluded from the analysis
[31], assuming that this variable has a poor empirical
contribution to the corresponding inferred cognitive
function. According this criterion, Digit Symbol cod-
ing, Digit spans forwards, and backwards subtests
of WAIS-III [29], and Commands from ADAS-Cog
[30], were each excluded from the corresponding
PCA analyses. The linear function of the original
variables from the factorial solution, was used as a
final standardized domain score, for each subject,
which we identified as a composite in this study.
Each cognitive domain corresponded to a CC domain
score that could be later analyzed using standard
procedures.
Neuroimaging acquisition and analysis
All subjects from the ACE study underwent a
structural MRI, FDG-PET, and PiB-PET within 30
days following the neurological and neuropsycho-
logical visits. All subjects from the AB255 study
underwent a structural MRI and FDG-PET. Imag-
ing data were analyzed using the Fundacio´ ACE
Pipeline for Neuroimaging Analysis, available at
http://detritus.fundacioace.com/.
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MRI
All MRI scans were performed with a 1.5T MR
scanner (Magnetom Symphony; Siemens Medical
Solutions, Erlangen, Germany). The protocol for the
acquisition of the MRI data was identical for all
subjects and consisted of 3D T1-weighted Sagital
MP-RAGE, 2D Axial T2-weighted TSE, 2D Axial
Fluid-Attenuated Inversion Recovery (FLAIR), 2D
Axial T2* Gradient Echo and 2D Axial Diffusion
Weighted Imaging. Brain images were also visu-
ally inspected by experienced clinicians who were
blinded to the participants’ demographic, anthropo-
metric, and clinical data. All MRI were acquired
before the PET and an expert neuroradiologist
excluded any form of vascular pathology over par-
ticipants. Subjects with MRI evidence of major
stroke, white matter hyperintensities, leukoaraiosis,
and lacunae were excluded.
Cortical reconstruction and volumetric segmenta-
tion was performed with the Freesurfer 5.3 image
analysis suite, which is documented and freely
available for download online (http://surfer.nmr.
mgh.Harvard.edu/). The technical details of these
procedures are also described in prior publications
[32, 33]. Freesurfer morphometric procedures have
been proven to show good test-retest reliability across
scanner manufacturers and across field strengths [34,
35]. The procedures for the measurement of corti-
cal thickness have been validated against histological
analysis [34] and manual measurements [33, 36].
A residual approach was used to adjust hippocam-
pal volume by total intracranial volume (ICV) [37].
The aHV was obtained with the following formula:
aHV = HV-b (ICV-<ICV>), where HV is the mean
value between right and left HV, <ICV> reflects the
group mean ICV value and b is the regression slope
between ICV and HV.
FDG-PET
The FDG-PET were acquired 60 min after
intravenous injection of approximately 370 MBq
of [18F]-FDG during 20 min. The imaging pro-
cessing and calculation of mean value for the
defined ROI were performed using the imag-
ing processing suite FSL, free available online at
http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/. Every individ-
ual scan was averaged and corrected. Then, the resul-
tant images were coregistered to Montreal National
Institute (MNI) standard space and mean value of
FDG-PET activity calculated for a composite region-
of-interest (ROI). This composite ROI was built with
a set of five ROIs (left and right angular gyri, bilat-
eral posterior cingulate gyrus, and left middle and
inferior temporal gyrus) based on coordinates cited
frequently in other FDG studies comparing AD, MCI,
and normal subjects in the ADNI (Alzheimer’s Dis-
ease Neuroimaging Initiative) database and available
in http://adni.loni.usc.edu/methods/research-tools/.
The SUVR was calculated normalizing by the
value of vermis/pons as described in Landau
et al. [38].
Notice that volumetric and FDG-PET analysis
carried on our data were made using the same
methods that ADNI site recommend. Information
about these analyses are available in ADNI website
(http://adni.loni.usc.edu/methods/).
PIB-PET from the ACE study
All these individuals also received a PIB-PET
scan. The PIB-PET was acquired 50 min after intra-
venous injection of 400 MBq of the radiotracer.
Every subject MRI was previously segmented using
Freesurfer. A cortical composite ROI was built with
the labels exported by Freesurfer segmentation on
Desikan-Killiany Atlas. The composite ROI included
four large cortical grey matter regions (frontal,
anterior/posterior cingulate, lateral parietal, lateral
temporal). The SUVR was calculated using the cere-
bellum as reference region [39, 40].
Apolipoprotein E (APOE) genotyping
APOE genotyping was performed for all subjects
as previously described by Hixson et al. [41] using the
amplification of genomic DNA, digestion with HhaI,
and further analysis of the restriction fragments.
Alzheimer’s disease neuroimaging initiative data
Additional data used in the preparation of this
study were obtained from the ADNI database
(http://adni.loni.usc.edu). The ADNI was launched in
2003 as a public-private partnership, with the primary
goal to assess relationships between serial MRI, PET,
other biological markers, and clinical and neuropsy-
chological assessment in the progression of MCI and
early AD.
The ADNI repository was explored for MCI
patients with PIB-PET images (n = 65) [42, 43], and
who were similar in age, gender, and educational
levels to the ACE study and in parental dataset the
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Table 2
Partial correlations between neuroimaging biomarkers and the five CCs domain scores in MCI subjects from the ACE study (n = 20) and the
AB255 study (n = 133)
CCs related to: (A) aHV (B) FDG-PET (C) PIB-PET
 p-value  p-value  p-value
Learning CC 0.09 0.74 0.06 0.82 – 0.02 0.92
0.13 0.12 0.05 0.59 NA NA
Delayed Recall CC – 0.02 0.94 0.06 0.82 – 0.61 0.003∗
0.27 0.01∗ 0.27 0.01∗ NA NA
Executive Functions CC 0.29 0.24 0.23 0.37 – 0.19 0.45
0.01 0.92 0.21 0.03 NA NA
Language CC 0.23 0.37 – 0.04 0.87 0.21 0.40
0.06 0.51 0.04 0.65 NA NA
Praxis CC 0.19 0.46 – 0.01 0.97 – 0.07 0.79
–0.08 0.33 0.13 0.14 NA NA
Values in regular print correspond to ACE study and values in italic correspond to AB255 study; CC, Cognitive Composite domain score; aHV,
adjusted hippocampal volume; , partial correlations adjusted by age, gender, and education; NA, not applicable; ∗Statistically significant
after Bonferroni’s correction p≤ 0.01.
AB255 study. From those with MCI, 54 subjects (34
PIB positive and 16 PIB negative) were labeled as
“MCI due to AD” with memory storage impairment.
Moreover, those MCI with structural MRI (n = 477)
and with FDG-PET (n = 336) were also downloaded
from the ADNI repository for a later comparison of
results obtained in this study.
The subtests used for the construction of the ADNI
CC domain score were the delayed recall on mem-
ory scores from ADAS-Cog scale and RAVLT. ADNI
PIB neuroimaging analysis was completed at Univer-
sity of Pittsburgh, PET Facility. The methods used
in this analysis are described at the ADNI website
(http://adni.loni.usc.edu/methods/pet-analysis).
An automated template-based method was used
to sample multiple ROIs on the ADNI PIB SUVR
image. The PIB SUVR was downloaded from the
ADNI website along with its corresponding ADNI
Processed 3 MR image. The MR image choice was
scanner dependent. The PIB SUVR image has been
co-registered to the first frame of the raw image file
and averaged across frames (for dynamic acquisitions
only), reoriented to Talairach space, intensity normal-
ized so that the average of voxels within the mask
was exactly 1, and smoothed to achieve a uniform
isotropic resolution of 8 mm FWHM. A set of four
ROIs were averaged to calculate the PiB SUVR in
the frontal cortex, anterior cingulate, parietal cortex
and precuneus. All the values were normalized to the
cerebellum uptake value. A description of the other
variables used is detailed in Supplementary Table 1.
Notice that the procedures to calculate the PIB SUVR
by the University of Pittsburgh at ADNI database and
along this study are completely different. So the data
could not be merged but any comparison must be done
between the final results.
Statistical analysis
Partial correlations, adjusted by age, gender, and
educational level, were carried out among every
CC domain score and the three neuroimaging
biomarkers, the aHV on MRI, FDG-PET SUVR,
and PIB-PET SUVR. This procedure was per-
formed for both the whole sample (the MCI and
the HC groups) and the MCI group alone. The
PIB-PET SUVR was compared to the aHV and
FDG-PET SUVR in order to contrast amyloid-
(A) burden within the MCI group, related to the
significant CCs domain scores. Further, a Kaplan-
Meier survival analysis was executed in order to
estimate survival times in MCI from the ACE
study. The aHV on MRI and FDG-PET results from
the AB255 study and PIB-PET results from ACE
study were replicated using data from the ADNI
website (http://adni.loni.usc.edu) and specifically, R
ADNIMERGE package (http://adni.bitbucket.org).
Cox proportional hazards with adjustments for age,
gender, and education were also completed from
ADNI data.
RESULTS
As can be seen in Supplementary Table 2, the corre-
lations between the three neuroimaging biomarkers
and the five CCs domain scores are strong for the
whole sample from the ACE study and the AB255
study.
This was expected since MCI and HC groups are
quite different for biomarkers and neuropsychologi-
cal CCs domains scores.
Within the ACE MCI study, there was only a sin-
gle significant partial correlation between PIB-PET
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Fig. 1. PIB SUVR related to the Delayed Recall CC established by aHV in the MCI group. aThe MCI subjects with the best performances on
the Delayed Recall CC domain score are shown with circles, bthose with intermediate performances are represented with triangles, cwhile
those with the worst performances are shown with squares. dAfter a median survival time of 20.6 months (SD: 15.5; range: 6–68), 17/20
(85%) of the MCI patients developed dementia; 15 (88.2%) with AD; and 2 (11.8%) with a mixed dementia (AD with cerebrovascular
disease).
SUVR and the Delayed Recall CC domain score
(= –0.61, p = 0.003) (Table 2C).
In our replication MCI sample from parental
dataset AB255, there was a significant partial cor-
relation between the aHV and the Delayed Recall
CC domain score (= 0.27, p = 0.01) (Table 2A), and
between the FDG-PET SUVR and Delayed Recall
CC domain score (= 0.27, p = 0.01) (Table 2B).
MCI subjects from the ACE study demonstrated
an A burden related to the Delayed Recall CC
domain score as established by aHV on MRI (Fig. 1)
and FDG-PET (Fig. 2). They were classified into
aHV+ (n = 17) and aHV- (n = 3) with a threshold of
aHV = 3.2 cm3, and into FDG+ (n = 18) or FDG-
(n = 2) with a threshold of FDG-PET SUVR = 1.3.
Those thresholds were the biomarker values that
better separated the HC and MCI groups for each
case. The A burden cut-off was taken as PIB-PET
SUVR = 1.5, for 12 PIB+ and 8 PIB- subjects. The
Delayed Recall CC domain score, naturally divided
the sample into positive and negative subjects by its
mean value of zero. Indeed, this is the threshold that
best separated HC and MCI groups.
After a median survival time of 20.6 months (SD:
15.5; range: 6–68), 17/20 (85%) of the ACE MCI
patients developed dementia; 15 (88.2%) with AD
and 2 (11.8%) with a Mixed Dementia (AD with
cerebrovascular disease) (Figs. 1 and 2). Over the
course of the observation, one of the MCI patients
died and was censored for the analysis of dementia
incidence. Among this group, Kaplan-Meier analy-
ses showed that the Delayed Recall CC was the best
domain score to predict conversion to dementia com-
pared to the other CCs (see Supplementary Table 3
and Supplementary Figure 1 for details); however,
this only showed a tendency to approach signif-
icance (Wald = 3.49; p = 0.06; Odds Ratio = 7.40)
(0.91–58.82 [95% CI]).
Finally, the correlation between the five CCs
domain scores and the three biomarkers was repli-
cated using the ADNI dataset (Table 3). The
partial correlations between the Delayed Recall
CC domain score and aHV on MRI (Table 3A),
FDG-PET (Table 3B), and PIB (Table 3C) were
the most significant in MCI from the ADNI
dataset.
After a median survival time of 6.5 months (SD:
5.4; range: 6 months-4years), 26/54 (48%) of the
ADNI MCI patients developed dementia, specifically
AD.
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Fig. 2. PIB SUVR related to the Delayed Recall CC established by FDG in the MCI group. aThe MCI subjects with the best performances
on the Delayed Recall CC domain score are shown with circles, bthose with intermediate performances are represented with triangles, cwhile
those with the worst performances are shown with squares. dAfter a median survival time of 20.6 months (SD: 15.5; range: 6–68), 17/20
(85%) of the MCI patients developed dementia; 15 (88.2%) with AD; and 2 (11.8%) with a mixed dementia (AD with cerebrovascular
disease).
Table 3
Partial correlations between neuroimaging biomarkers and the five CCs domain scores in MCI subjects from the ADNI dataset
CCs related to: (A) aHV (B) FDG-PET (C) PIB-PET
 p-value  p-value  p-value
Learning CC 0.35 (n = 477) 2.95 e–15∗∗ 0.23 (n = 336) 1.51 e–05∗∗ – 0.39 (n = 54) 0.004
Delayed Recall CC 0.50 (n = 477) 1.56 e–31∗∗ 0.30 (n = 336) 2.17 e–08∗∗ – 0.42 (n = 54) 0.002∗
Executive Functions CC 0.18 (n = 479) 5.98 e–05∗∗ 0.29 (n = 334) 4.88 e–08∗∗ – 0.35 (n = 54) 0.01
Language CC 0.14 (n = 478) 0.002∗ 0.14 (n = 337) 0.01 – 0.19 (n = 54) 0.19
Praxis CC NA NA NA NA NA NA
CC, Cognitive Composite domain score; aHV, adjusted hippocampal volume; , partial correlations adjusted by age, gender, and education;
∗Statistically significant after Bonferroni’s correction p≤ 0.01; ∗∗p≤ 0.001; NA, not applicable on ADNI.
Within MCI with PIB-PET, Cox proportional haz-
ards with adjustments for age, gender, and education
showed that the Delayed Recall CC significantly pre-
dicted conversion to AD dementia (Wald = 11.32;
p = 0.001; Odds Ratio = 2.51) (1.46 – 4.29 [95% CI])
(see Supplementary Figure 2 for details).
DISCUSSION
This work explored the relationship between five
CCs domain scores, and three AD neuroimag-
ing biomarkers covering neurodegeneration and A
deposition, within probable MCI [12, 13] subjects
with memory storage impairment [9]. As previously
reported [9], the probable MCI condition had higher
risk of early conversion to dementia, mainly AD
than the rest of MCI individuals. Remarkably, those
Pr-aMCI subjects with storage memory impairment
had the most and closest risk of conversion to demen-
tia, mainly AD compared to the other MCI subtypes.
Of note, since the aim of our study was include only
the Pr-aMCI-storage subtype subjects, we reported as
a unique condition that they must all have a memory
loss characterized as being one of impaired storage,
that is, independently if they had single or multiple
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domains impaired. However, all MCI had deficits in
multiple cognitive domains. Our data supports that
the traditional amnestic single-domain aMCI (aMCI-
sd) [20] is rarely diagnosed when a comprehensive
neuropsychological battery is applied, because other
cognitive deficits are frequently found when neu-
ropsychological evaluation is expanded [44].
One of our central goals was to extend the
limited literature of CCs domain scores combined
with neuroimaging biomarkers in this population. In
particular, focus on the relation with A burden, dis-
cussed in more detail later. Then we analyzed the
correlation between these two magnitudes. We found
that only poorer performances on Delayed Recall CC
domain score are related to reduced hippocampal vol-
ume, greater hypometabolism, and also greater A
burden. Other CCs domain scores, such as executive
functions, language, and praxis, were not found to be
related to neuroimaging biomarkers used. Our results
are according to previous studies that reported that
poorer Delayed Recall was related to reduced hip-
pocampal volume as well as greater hypometabolism
in MCI patients who were near to AD dementia con-
version [45–51].
However, our main finding is that the A burden of
the MCI subjects, related to the Delayed Recall CC
domain score performances, did not allow classifying
all MCI subjects as Prodromal AD in either aHV on
MRI or FDG-PET. Instead, some of them had high
and other low A burden. Importantly, that as men-
tioned above, we included subjects in the worst case
situation in order to distinguish it, understanding that
the MCI sample, all Pr-aMCI-storage subtype, has a
high homogeneity phenotype, and besides this, con-
tains some members with closely AD-like cognitive
and biomarker pattern who are likely to convert in the
near future. Furthermore, observed APOE 4 allele
enrichment in the ACE study (70.0%), closely resem-
bled histopathological series reported in AD [52]. In
fact, almost all of MCI converted to dementia, mainly
developed clinical AD.
As a fact, while all subjects were positive at base-
line for at least one neuroimaging biomarker, only 11
(55%) subjects were positive for the three biomark-
ers at the same time. In contrast, 17 (85%) subjects
were positive for aHV, 18 (90%) were positive for
FDG-PET, and 12 (60%) were positive for PIB-PET.
Also, 15 (75%) subjects were positive for aHV and
FDG-PET, 11 (55%) were positive for aHV and PIB-
PET, and 11 (55%) were positive for FDG-PET and
PIB-PET. Regarding the Delayed Recall CC domain
score, all subjects had a negative value.
Hence, Pr-aMCI-storage subjects with higher A
burden could be considered canonical prodromal
AD (represented in the right bottom corner of both
figures). All of the subjects with both greater hip-
pocampal atrophy and hypometabolism could find
representation in the biomarker model of pure AD
[53–56]. In contrast, it is likely that MCI subjects
with lower A burden behave like SNAP (suspected
non-Alzheimer’s pathology) subjects, i.e., those indi-
viduals with neuroimaging/biomarker evidence of
AD-like neurodegeneration without clinical amyloi-
dosis [57] (represented in the left bottom corner of
both figures). All of these subjects could find rep-
resentation on the neurodegeneration-first biomarker
model of late-onset AD [53–56]. Note that one sub-
ject might be showing low performances on the
Delayed Recall CC domain score, even before show-
ing high A burden. In addition, other subjects with
high A burden do not show enough hippocampal
atrophy or hypometabolism to be classified as pro-
dromal AD (top right corner of both figures). All of
them could find representation in the amyloid-first
biomarker model of late-onset AD [53–56].
Nevertheless, two of our MCI subjects could not
find representation in any of the three Jack’s models
[53–56] (left top corner of both figures). Note that
although both developed AD dementia, were in the
boundaries to be considered with high A burden
based on aHV on MRI, and on FDG-PET SUVR.
For a big fraction of our MCI subjects, clinical
and cognitive features that are: the “probable” clin-
ical condition, the memory storage impairment, and
the impaired Delayed Recall CC domain score pre-
cedes in this study amyloid and neurodegeneration
biomarkers. This finding was unexpected given the
fact that previous studies with MCI reported that the
core biomarker pattern provided clinical evidence of
the AD model in patients with MCI [58, 59]. The
selection of this MCI population in clinical trials with
the poorer performances on the Delayed Recall CC
domain score could avoid substantial heterogeneity in
biomarkers previously reported within amnestic MCI
who were clinically similar [60].
Our main finding of this specific clinical-cognitive
phenotype MCI observed before amyloidosis is the
first reported in the literature. That is, a big frac-
tion of our MCI subjects that converted to clinical
AD dementia have not found representation in line
with the current pathophysiologic model of AD; even
two of our MCI subjects have not found it in any of
the three different sets of biomarker models Jack and
colleagues proposed [53–56].
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After a median survival time of 20.6 months (SD:
15.5; range: 6–68), 17/20 (85%) of the ACE MCI
patients developed dementia; 15 (88.2%) AD type;
and 2 (11.8%) mixed dementia (AD with cerebrovas-
cular disease). This points out the importance of
follow-up in this MCI group. However, further stud-
ies including a more extensive longitudinal clinical
follow-up and anatomopathological data would be
needed to corroborate these results.
With regard to ADNI, the procedures for the
calculation of PIB SUVR and the Delayed Recall
CC domain score slightly differed between samples.
Also, the composite scores calculated on both
datasets are not exactly the same. The corresponding
CC domain score for the Delayed Recall differed on
the visual memory by the ROCF test from the ADNI
and the ACE and the AB255 studies, but both reflects
the performance on the same cognitive domain. So
although data cannot be merged across datasets, any
comparison should be done between the statistical
results. In addition, with our ADNI replication, we
confirm that the Delayed Recall is the optimal CC
domain score to look for prodromal AD, when com-
pared to the other CC domains. Other CCs such
as Learning and Executive functions domain scores
were found related to hippocampal volume and FDG-
PET, previously associated in MCI and AD patients
with increasing disease severity [61].
One of the limitations of this study is firstly the
lack of amyloid PET in parental dataset AB255; thus,
the sample size of subjects with amyloid PET in
ACE study was small. This fact could explain that
the Delayed Recall CC domain score only showed a
tendency to approached significance toward superi-
ority with respect to the other CCs domain scores,
as a predictor of conversion to dementia. However,
in our replication from ADNI, the Delayed Recall
was the best CC domain score as a predictor of
conversion to AD. Secondly, we were not able to mea-
sure sensitivity and specificity values because of the
small sample sizes. Our results are limited to those
Pr-aMCI-storage subtype subjects and therefore, are
not applicable or extendable to the majority of MCI
cases. Further studies incorporating a more hetero-
geneous MCI group phenotype, i.e., including the
possible/probable and amnestic/non-amnestic MCI
subtypes [9] could be considered.
In conclusion, according to our results, we strongly
suggest selecting those subjects within Pr-aMCI-
storage subtype with the worst performances on
Delayed Recall CC domain score in order to max-
imize cost-benefits of clinical trial recruitment.
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